%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2017-07-17T10:50:23-04:00
2017-07-17T10:50:26-04:00
2017-07-17T10:50:26-04:00
Adobe InDesign CC 2017 (Windows)
uuid:f5acca05-764b-4f56-8869-077a2cdc98f3
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:86ce188d-a08a-c94b-9cc7-50e80860f0ec
proof:pdf
xmp.iid:364c96e6-49fd-8340-bf1b-334cae691ab5
xmp.did:ed97ec5e-6faf-5042-a649-00adf15747dc
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2017 (Windows)
/
2017-07-17T10:50:23-04:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
5 0 obj
<>
endobj
3 0 obj
<>
endobj
7 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
8 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
11 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
13 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
14 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text/ImageC]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
41 0 obj
<>stream
q
/GS0 gs
0 TL/Fm0 Do
Q
BT
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-0.01 Tc 8.5 0 0 8.5 171.2281 427.438 Tm
(1.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(The safest and most effective primary)-10 ( )]TJ
0 -1.2 TD
[(prevention of myocardial infarction in atrial)-10 ( )]TJ
T*
(\037brillation patients is:)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 Tc 0 -1.729 TD
(a. aspirin.)Tj
0 -1.729 TD
(b. vitamin K antagonist.)Tj
0 -1.729 TD
(c. both aspirin and vitamin K antagonist.)Tj
T*
(d. both aspirin and vitamin K antagonist plus )Tj
0 -1.2 TD
(clopidogrel.)Tj
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-0.01 Tc -1.588 -2.894 Td
(2.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(The major challenge for an entirely leadless)-10 ( )]TJ
0 -1.2 TD
[(pacemaker and implantable cardioverter)-10 ( )]TJ
0 -1.2 TD
(de\037brillator combination is:)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 Tc 0 -1.729 TD
[(a. appropriate shock delivery)92 (.)]TJ
T*
(b. reliable pacing.)Tj
T*
(c. communication between the devices.)Tj
T*
(d. effective anti-tachycardia pacing.)Tj
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-0.01 Tc -1.588 -2.894 Td
(3.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(In post-myocardial infarction hospital)-9.9 ( )]TJ
0 -1.2 TD
[(survivors without heart failure or reduced left)-10 ( )]TJ
T*
(ventricular function, beta-blockers are )Tj
/T1_2 1 Tf
0.01 Tw (not)Tj
/T1_0 1 Tf
0 Tc 0 Tw 17.804 0 Td
( )Tj
-0.01 Tc -17.804 -1.2 Td
(useful for:)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 Tc 0 -1.729 TD
(a. controlling blood pressure.)Tj
0 -1.729 TD
(b. controlling heart rate with atrial )Tj
0 -1.2 TD
(\037brillation.)Tj
0 -1.729 TD
(c. treating ventricular tachyarrhythmias.)Tj
0 -1.729 TD
[(d. reducing one-year mortality)92 (.)]TJ
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-0.01 Tc 21.308 37.341 Td
(4.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(Patients < 50 years of age treated with alcohol)-9.9 ( )]TJ
0 -1.2 TD
[(septal ablation for symptomatic hypertrophic)-10 ( )]TJ
T*
[(cardiomyopathy compared to older patients)-10 ( )]TJ
T*
(had lower rates of:)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 Tc 0 -1.729 TD
(a. procedural death.)Tj
T*
(b. cardiac tamponade.)Tj
0 -1.729 TD
(c. permanent pacemaker required.)Tj
0 -1.729 TD
(d. All of the above)Tj
/CS0 cs 1 scn
/GS0 gs
/T1_0 1 Tf
-0.01 Tc -1.588 -2.894 Td
(5.)Tj
/Span<>> BDC
[( )-94.4 ( )]TJ
EMC
1.588 0 Td
[(The relationship between door)55 (-to-furosemide)-9.9 ( )]TJ
0 -1.2 TD
(and hospital mortality in acute heart failure is:)Tj
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
0 Tc 0 -1.729 TD
(a. linear through 180 minutes.)Tj
T*
[(b. non-linear)111 (, plateauing at 100 minutes.)]TJ
T*
(c. exponential, rising rapidly after 60 )Tj
0 -1.2 TD
(minutes.)Tj
0 -1.729 TD
(d. curvilinear more than 90 minutes.)Tj
-0.03 Tc 10 0 0 10 163.5162 731.28 Tm
[(implanted safely and successfully)92 (, a standard)-30 ( )]TJ
0 -1.2 TD
(S-ICD with updated \037rmware could com)Tj
0 Tc (-)Tj
-0.03 Tc T*
[(municate reliably with the LP and command)-30 ( )]TJ
T*
[(delivery of A)74 (TP)129 (, and LP pacing did not impede)-30 ( )]TJ
T*
(successful rhythm discrimination by the S-)Tj
T*
[(ICD. The modular nature of the system could)-30 ( )]TJ
T*
[(allow for the addition of an LP for a patient)-29.9 ( )]TJ
T*
[(who already has an S-ICD, and vice versa, as)-30 ( )]TJ
T*
(clinical requirements dictate.)Tj
0 -2.4 TD
[(Clearly)91.9 (, more study will be necessary before)-29.9 ( )]TJ
0 -1.2 TD
[(the system is ready for clinical implementation;)-30 ( )]TJ
T*
[(the safety and ef\037cacy requires longer)55 (-term)-30 ( )]TJ
T*
[(demonstration in human subjects. However)111 (, it)-30 ( )]TJ
T*
[(may not be long before such a system becomes)-30 ( )]TJ
T*
[(an attractive tool in our armamentarium, as)-30 ( )]TJ
T*
[(the S-ICD component already has proven itself)-30 ( )]TJ
T*
[(to meet those minimum requirements for an)-30 ( )]TJ
T*
[(ICD, and the LP mainly serves to augment its)-30 ( )]TJ
T*
[(safety and ef\037cacy)92 (. Reliable sensing and pacing)-30 ( )]TJ
T*
[(from leadless devices also has already been)-30 ( )]TJ
T*
(demonstrated, so the primary feature requir)Tj
0 Tc 17.544 0 Td
(-)Tj
-0.03 Tc 2.742 25.2 Td
[(ing further long-term study is communication)-30 ( )]TJ
T*
(from the S-ICD to the LP to enable coordi)Tj
0 Tc (-)Tj
-0.03 Tc T*
[(nated therapy)92 (. Conducted communication)-30 ( )]TJ
T*
(\(intrabody device-device electrical communi)Tj
0 Tc (-)Tj
-0.03 Tc T*
[(cation using the body tissue as a conductor\))-30 ( )]TJ
T*
[(poses inherent risks: failed communication)-30 ( )]TJ
T*
[(\(because of inadequate signal transmission)-30 ( )]TJ
0 Tc T*
(or electromagnetic interference\) that could )Tj
T*
[(result in failure to deliver A)74.1 (TP)129 (, and perhaps )]TJ
T*
(more worrisome, miscommunication result)Tj
(-)Tj
T*
[(ing in inadvertent delivery of A)74.1 (TP)129 (. The )]TJ
T*
(authors discussed two common sense safety )Tj
T*
(features to minimize the risk of communi)Tj
(-)Tj
T*
(cation interference between the S-ICD and )Tj
T*
[(the LP)129 (, and rigorous testing will be neces)]TJ
(-)Tj
T*
[(sary to ensure reliability)92.1 (.)]TJ
0 -2.4 TD
[(Ultimately)92.1 (, by addressing the most impor)]TJ
17.686 0 Td
(-)Tj
-17.686 -1.2 Td
(tant limitation of the current S-ICD, this )Tj
0 -1.2 TD
(combined system may offer the potential )Tj
T*
(advantages of a leadless device to a much )Tj
T*
(broader population of patients. )Tj
/C2_0 1 Tf
<0084>Tj
ET
q
/GS0 gs
84.5798923 0 0 169.1597846 36.6400261 101.9999749 cm
/Im0 Do
Q
endstream
endobj
42 0 obj
<>
endobj
44 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Subtype/Form>>stream
/CS0 cs 0.07 scn
/GS0 gs
18 89.28 120.33 666.72 re
f
18 36 539.325 53.473 re
f
BT
0 0 0 1 k
/GS1 gs
/TT0 1 Tf
0 Tc 0 Tw 0 Ts 100 Tz 0 Tr 7 0 0 7 27.8983 78.3659 Tm
(Interested in reprints or posting an article to your )Tj
0 -1.143 TD
[(company)-55.8 (\222s site? There are numerous opportunities for )]TJ
0 -1.143 TD
(you to leverage editorial recognition for the benefit of )Tj
0 -1.143 TD
(your brand. Call us at \(800\) 688-2421 or email us at )Tj
T*
[(R)17.6 (eprints@AHCMedia.com.)]TJ
25.217 4.571 Td
(Discounts are available for group subscriptions, multiple )Tj
T*
(copies, site-licenses, or electronic distribution. For pricing )Tj
0 -1.143 TD
(information, please contact our Group Account Managers )Tj
0 -1.143 TD
(at Groups@AHCMedia.com or \(866\) 213-0844.)Tj
19.48 0 Td
( )Tj
5.737 3.429 Td
[(T)175 (o reproduce any part of AHC newsletters for )]TJ
T*
(educational purposes, please contact The Copyright )Tj
0 -1.143 TD
(Clearance Center for permission at info@copyright.com )Tj
0 -1.143 TD
(or \(978\) 750-8400.)Tj
ET
/CS0 CS 1 SCN
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 138.6633 754.5 cm
0 0 m
437.337 0 l
S
Q
/CS0 cs 1 scn
163.328 445.32 392.414 17.367 re
f
0.25 w
163.391 95.125 392.225 350.069 re
S
BT
0 0 0 0 k
12 0 0 12 304.0168 449.4156 Tm
(CME/CE QUESTIONS)Tj
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
7 0 0 7 26.64 742.5959 Tm
(PHYSICIAN EDITOR)Tj
( )Tj
/TT0 1 Tf
0 -1.214 TD
[(Michael H)17.9 (. Crawford, MD)]TJ
/TT1 1 Tf
0 -1.214 TD
[(P)35.7 (rofessor of Medicine)]TJ
0 -1.214 TD
(Chief of Clinical Cardiology )Tj
10.628 0 Td
( )Tj
-10.628 -1.214 Td
(University of California )Tj
8.894 0 Td
( )Tj
-8.894 -1.214 Td
[(San F)54.9 (rancisco)]TJ
/T1_0 1 Tf
0 -2.429 TD
(PEER REVIEWER)Tj
/TT0 1 Tf
0 -1.214 TD
(Susan Zhao, MD)Tj
/TT1 1 Tf
0 -1.214 TD
(Director )Tj
( )Tj
0 -1.214 TD
[(Adult Echocardiography L)17.3 (aboratory)]TJ
0 -1.214 TD
[(Associate Chief)34.9 (, Division of Cardiology)86.4 (, )]TJ
0 -1.214 TD
(Department of Medicine)Tj
0 -1.214 TD
[(Santa Clara V)53.9 (alley Medical Center)]TJ
/T1_0 1 Tf
0 -2.429 TD
(NURSE PLANNER)Tj
/TT0 1 Tf
0 -1.214 TD
[(Aurelia Macabasco)-18.9 (-)-36.5 (O)17.8 (\222Connell, PhD, )]TJ
0 -1.214 TD
[(A)17.5 (CNP)78 (-BC, RN, PHN, F)36.7 (AHA)]TJ
/TT1 1 Tf
0 -1.214 TD
[(Associate P)35.3 (rofessor)]TJ
0 -1.214 TD
[(Azusa P)54.6 (acific University School of )]TJ
0 -1.214 TD
(Nursing)Tj
/T1_0 1 Tf
0 -2.715 TD
[(EDITORIAL ADVISOR)92.1 (Y BOARD)]TJ
/TT0 1 Tf
0 -1.214 TD
(Joshua D. Moss, MD)Tj
/TT1 1 Tf
0 -1.214 TD
[(Associate P)35.3 (rofessor of Clinical Medicine)]TJ
0 -1.214 TD
(Cardiac Electrophysiology)Tj
0 -1.214 TD
(Division of Cardiology)Tj
T*
[(University of California, San F)54 (rancisco)]TJ
/TT0 1 Tf
0 -2.429 TD
[(V)54.9 (an Selby)87.2 (, MD)]TJ
/TT1 1 Tf
0 -1.214 TD
[(Assistant P)34.8 (rofessor of Medicine, )]TJ
T*
[(University of California, San F)54 (rancisco )]TJ
0 -1.214 TD
(Cardiology Division, Advanced Heart )Tj
T*
[(F)35.9 (ailure Section)]TJ
/TT0 1 Tf
0 -2.5 TD
(Jeffrey Zimmet, MD, PhD)Tj
/TT1 1 Tf
0 -1.214 TD
[(Associate P)35.3 (rofessor of Medicine)]TJ
0 -1.214 TD
[(University of California, San F)54 (rancisco)]TJ
0 -1.214 TD
[(Director)100.5 (, Cardiac Catheterization )]TJ
0 -1.214 TD
[(L)17.4 (aboratory)]TJ
0 -1.214 TD
[(San F)54.9 (rancisco V)54.9 (A Medical Center)]TJ
/T1_0 1 Tf
0 -2.429 TD
(EDITOR)Tj
/TT1 1 Tf
( )Tj
/TT0 1 Tf
0 -1.214 TD
(Jonathan Springston)Tj
/T1_0 1 Tf
0 -2.429 TD
(EXECUTIVE EDITOR)Tj
/TT1 1 Tf
( )Tj
/TT0 1 Tf
0 -1.214 TD
(Leslie G. Coplin)Tj
/T1_0 1 Tf
0 -2.429 TD
(AHC MEDIA EDITORIAL )Tj
0 -1.214 TD
(GROUP MANAGER)Tj
/TT0 1 Tf
0 -1.214 TD
[(T)175 (errey L. Hatcher)]TJ
/T1_0 1 Tf
6 0 0 6 26.64 294.5944 Tm
[(SENIOR ACCREDIT)74.1 (A)74 (TIONS OFFICER)]TJ
10 0 0 10 133.0305 294.5944 Tm
( )Tj
/TT0 1 Tf
6 0 0 6 26.64 287.0944 Tm
(Lee Landenberger)Tj
ET
endstream
endobj
45 0 obj
<>/Filter/FlateDecode/Height 940/Intent/RelativeColorimetric/Length 79820/Name/X/SMask 49 0 R/Subtype/Image/Type/XObject/Width 470>>stream
H엉WSwaMll
(**T;tF\ZZiVzuF!$!"Pd) dkK;9}ww2t.K Db uFSGo]f" Xpj5Ce
_}Mu֜9:>H
jL \1eBHn$C'ɖ}ì{3#tMhO
0$R@b[Ypn%o2 /jLYfXo?j? %t'ݒpVPG-# \A0#1>m{K>r
WogAAfD$5 EN;֖rUH,x eZsWǏtw;2p~ ^?)N44hRA WHbwt>5U(x Pl6*(X ;wMX,le-RKe ^iVh1)mVR"Q ^iV"iSO+xl מ=6pU_ ^OH\?C<0 z!u)a` iV̒^ |ih_ \ P 00 B P 00 B P 00 B P 00 B PB"-q -kSCG*>ȅ
(L
&4LE<[h;X3D!9u|tHKuuϚs*ܼ%;n% EɣF`\'P-YGǎ^8իgΔ[f-}G{S@p_-)ޏNF3}nyk`B~RNcfsCï((譩j79x:99#(SG~xކ
>qR]uM[5f>+T!V:wZwud
Lۤ{l ھlʆ驭͊Yeؔ1CJJ>uK^ Sn]Yi_}C˅7g.It1$eZk^~bGaeUN?^SWe`KcvII>ki49)?7*Ckrg_%Bpg'mz:ה5ns50%rnP2m.YJS&7'wݺSlי=w sbStOũ 5^26lO>ZY:$Rf.T41CDd$sk
]jU{@QABG~JKݚnje凂';..-mt`f;w2#K,;t}e1q%.&Wl'F{heKup>ĚxG>GO9=y>{anmF'@8TRI/}S%0mB`Q4F&\W]#I0_D@:F&gS{21ظz!-nxZU&jxj``|QJ ̙C{IK,#"mmv&8_Jb~WјȢ'di^sxpAͪ
qD(Yx2Ah>>i82ک9DnnɞMo(~DGomeț>Iu!eX
0kh)q̭րH&y ixך~NsTm_KVp%0jZ*z UwΎzHZ"w`GSCkREjߊ}K*'.naV>]W]MT,QX64)-v_ʼ4 <k@ɝ;],ȄeV+ɒy2&0bu&,H~>>ꓧh\I$L)4AdsHG }n$%]|5}iV(\u`PV>♳b\x{st:]HFOd&y i/?3_ IMmT, I)T~:ebhFxBiSPSGJms8]SåKBFXuC]љ̤kQWQ?y&0nS[ܡkrq_!*dI8%-?o_~SIAˑ;bZH:s*DPJ6je;dV}&| 砗",YTq|zqB$uyK`NcX
4CQH1?V
ӫ